Weekly View

ICER Weekly View 04-21-17

From the desk of Mitchell Stein   Good morning. Rumors of a new healthcare deal in Congress have been greatly exaggerated; instead, expect the focus next week to be on the minor issue of funding the government. While all that is going on in DC, this week we’ll look at: ICER in the news – […]

Read More

ICER Weekly View 04-14-17

From the desk of Mitchell Stein   Good morning. If anyone thought that Congress being on recess coupled with the arrival of Passover and Easter meant this would be a quiet week, they were wrong. This week we’ll look at: ICER in the news – Release of the final report on rheumatoid arthritis and the […]

Read More

ICER Weekly View 04-07-17

From the desk of Mitchell Stein   Good morning. It seems like my standard intro is to say there is a lot going on in the world today that I won’t talk about… It fits again today, doesn’t it? That said, the world continues to turn, and there continues to be a lot of news […]

Read More

ICER Weekly View 03-31-17

From the desk of Mitchell Stein   Good morning. After last week’s events around the AHCA, you might think that Washington would take this week to regroup. You’d be wrong. Lots of news to talk about both inside and outside the beltway. Today we’ll look at: ICER in the news – Dupixent’s approval and pricing, ICER […]

Read More

ICER Weekly View 03-24-17

From the desk of Mitchell Stein   Good morning. Today’s healthcare focus is centered on what will happen with the house vote on the AHCA. While outside the purview of this newsletter, I will point out that today’s manager’s amendment to allow states to redefine the essential health benefits package puts both prescription drug coverage […]

Read More

ICER Weekly View 03-17-17

From the desk of Mitchell Stein   Good morning and happy Saint Patrick’s Day! ☘️ So much news, so little time. Today we’ll look at: ICER in the News – ICER more transparent than NICE, update to ICER’s PCSK9 work, ICER recognizes the National MS Society with a leadership award, RA evidence report released, and new […]

Read More

ICER Weekly View 03-10-17

From the desk of Mitchell Stein   Good morning. This week’s dominant healthcare story, the release of the Republican ACA replacement bill, is beyond the scope of this blog (to get my reaction to that story, you’ll have to follow me on Twitter). However, we have a lot of pharma news to talk about. This […]

Read More

ICER Weekly View 03-03-17

From the desk of Mitchell Stein   Good morning. I hope everyone had a good week. As always, we have a lot to cover. Here are today’s categories and stories: ICER in the News – An interview with Dan Ollendorf, orphan drugs, value-framework revisions, ovarian cancer drug review, and release of New and Noteworthy Inside […]

Read More

ICER Weekly View 02-24-17

From the desk of Mitchell Stein   Good morning. Another week, another avalanche of news. I received some positive feedback regarding using sections to make things more manageable, so for now, we’ll stick with it. This week starting off with ICER in the News, followed by four subcategories under Pharmaceutical news. ICER in the News […]

Read More

ICER Weekly View 02-17-17

From the desk of Mitchell Stein   Good morning. In the week since we’ve talked, I’ve been buried both literally and figuratively. Here in Portland ME, we’ve had over 30 inches of snow this week, while nationally, the “news” just keeps on coming. To help with the volume, today I’ve divided our stories into four […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP